Kintara Therapeutics and TuHURA Biosciences Announce Corporate and Clinical Updates

Kintara Therapeutics, Inc. and TuHURA Biosciences, Inc. provided recent updates on their corporate and clinical advancements. In April 2024, both companies signed a definitive merger agreement, under which TuHURA will merge into Kintara. This transaction is expected to finalize in Q3 2024.

Kintara’s shareholders will hold approximately 5.5% of the combined entity, which includes a contingent value right tied to the enrollment of 10 patients in Kintara’s REM-001 study. Furthermore, TuHURA plans to advance a Phase 3 trial for its personalized cancer vaccine, IFx-2.0, in H2 2024 under the FDA's accelerated approval pathway.

Recent clinical milestones include the enrollment and dosing in Kintara’s REM-001 study for cutaneous metastatic breast cancer. By June 2024, four patients had been dosed, with further screening to commence soon at additional medical centers. Most of the study's costs are covered by a $2 million NIH grant.

Key upcoming milestones include the merger completion in Q3 2024 and beginning TuHURA’s Phase 3 trial in the second half of 2024. Additionally, by Q4 2024, Kintara aims to complete enrollment of REM-001 study participants.